Intra-Uterine Contraceptive Devices Market Report 2026

The intra-uterine contraceptive devices market size has grown strongly in recent years. It will grow from $3.45 billion in 2025 to $3.68 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rising awareness of family planning and contraception adoption, government-led population control and reproductive health programs, increasing access to gynecology clinics and maternal healthcare services, improvement in healthcare infrastructure in developing regions, growing preference for long-acting reversible contraceptive methods.

The intra-uterine contraceptive devices market size is expected to see strong growth in the next few years. It will grow to $4.78 billion by 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for minimally invasive and user independent contraceptive solutions, expansion of women-centric healthcare awareness campaigns, rising adoption of hormonal and bioactive advanced intrauterine systems, growing focus on reducing unintended pregnancies globally, continuous innovation in biocompatible and drug eluting device technologies. Major trends in the forecast period include robotics assisted intrauterine device insertion procedures, industry 4.0 enabled contraceptive manufacturing automation, iot enabled smart medical device tracking and inventory management, blockchain based contraceptive supply chain traceability systems, electric mobility supported mobile reproductive healthcare outreach services.

The rising awareness about family planning is anticipated to propel the growth of the intra-uterine contraceptive devices market coming years. Family planning awareness is the understanding and knowledge among individuals and couples about controlling the number and spacing of children through the use of contraceptive methods. The rise in awareness about family planning is due to expanding public health education campaigns that promote reproductive health and informed contraceptive choices. Intrauterine contraceptive devices help strengthen family planning practices by offering long-term, reliable, and reversible contraception that supports effective pregnancy planning and birth spacing. For instance, in July 2025, according to a report published by the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, the global uptake of modern contraceptive methods reached approximately 874 million women in 2025, with a further 70 million women anticipated to gain access to family planning services by 2030, reflecting continued expansion in reproductive healthcare coverage and utilization. Therefore, the rising awareness about family planning is driving the growth of the intra-uterine contraceptive device market.

Leading companies operating in the intra-uterine contraceptive devices market are focusing on developing innovative products, such as hormone-free intrauterine systems to enhance patient comfort and expand non-hormonal contraceptive options. A hormone-free intrauterine system is a long-acting contraceptive device placed in the uterus that prevents pregnancy using non-hormonal materials, typically copper, to create a spermicidal intrauterine environment. For example, in February 2025, Sebela Pharmaceuticals Inc., a US-based pharmaceutical company specializing in gastroenterology and women’s health, announced US Food and Drug Administration approval of MIUDELLA. The product uses a flexible nitinol frame with a lower copper dose while maintaining high contraceptive effectiveness, supported by a preloaded delivery system designed for ease of insertion. Its introduction is significant as it represents the first hormone-free intrauterine device approval in over four decades in the United States, highlighting renewed innovation in non-hormonal contraceptive technologies.

In April 2024, Aspivix SA, a Switzerland-based medical device manufacturer, formed a partnership with Bayer to speed up the adoption of an innovative cervical stabilization device used in intrauterine procedures. Through this agreement, the companies aim to increase market uptake of intrauterine contraceptive devices by improving patient comfort during insertion procedures, thereby reducing pain-related barriers and improving overall acceptance of these procedures among patients and healthcare professionals. Bayer AG is a Germany-based provider of pharmaceuticals, women’s health products, and contraceptive solutions, including intrauterine systems, with a strong global presence in reproductive healthcare.

Major companies operating in the intra-uterine contraceptive devices market are AbbVie Inc., Bayer AG, Meril Life Sciences Pvt. Ltd., CooperSurgical Inc., Sebela Pharmaceuticals Inc., DKT International Inc., HRA Pharma Inc., Pregna International Limited, Egemen International, Zhejiang Daji Medical Instruments Co. Ltd., Medicines360, SMB Corporation of India, HLL Lifecare Limited, Injeflex Ind And Com Ltda, Gynocare Services Pvt Ltd., Aetos Pharma Pvt Ltd., Eurogine S. L., Mona Lisa N. V., Ocon Medical Ltd., Prosan International B. V.

North America was the dominating region in the intra-uterine contraceptive devices market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the intra-uterine contraceptive devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the intra-uterine contraceptive devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intra-uterine contraceptive devices market consists of sales of T-shaped framed devices, frameless intrauterine systems, levonorgestrel-releasing intrauterine systems, and silver-core intrauterine devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.